LONDON, UK / ACCESSWIRE / December 28, 2017 / Active-Investors.com has just released a free research report on Alexion Pharma, Inc. (NASDAQ: ALXN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALXN as the Company's latest news hit the wire. On December 26, 2017, the Company declared that the Ministry of Health, Labor, and Welfare (MHLW) in Japan has approved Soliris® (eculizumab) as a treatment for patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin (IVIG) therapy or plasmapheresis (PLEX). Soliris is the first and only complement inhibitor approved in Japan as a treatment for these patients.Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Alexion Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ALXN

The Company submitted an application to Japan's MHLW to extend the indication for Soliris® as a potential treatment for patients with refractory gMG in March 2017.

Approval is Based on Comprehensive Clinical Data from Phase-3 REGAIN Study

MHLW approval in Japan is based on the new indication of Soliris® on comprehensive clinical data from the Phase-3, randomized, double-blind, placebo-controlled, multicenter REGAIN study (ECU-MG-301). In the Phase-3 REGAIN study and its ongoing open-label extension study, Soliris® demonstrated treatment benefits for patients with anti-AChR antibody-positive gMG who had previously failed immunosuppressive treatment and continued to suffer from significant unresolved disease symptoms, which can include difficulties seeing, walking, talking, swallowing and breathing. These patients are at an increased risk of disease exacerbations and crises that may require hospitalization and intensive care and may be life-threatening.

FDA and EU Approved Soliris For Treatment of Patients With gMG

On October 23, 2017, the US Food and Drug Administration (FDA) approved Soliris® as a treatment for adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. In August 2017, European Commission (EU) also approved Soliris® for the treatment of refractory gMG in adults who are anti-acetylcholine receptor antibody-positive. Soliris is the first® and only complement-based therapy approved in the EU for this ultra-rare subset of patients.

About Soliris® (eculizumab)

Soliris® is a first-in-class terminal complement inhibitor discovered, developed, and commercialized by Alexion. Soliris® works by inhibiting terminal complement, a part of the immune system that, when activated in an uncontrolled manner, plays a role in serious diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis.

About Generalized Myasthenia Gravis (gMG)

Myasthenia gravis (MG) is a debilitating, chronic, long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be sudden. Those affected often have a large thymus gland or develop a thymoma. The disease can occur at any age but most commonly begins for women before the age of 40 and men after the age of 60.

About Alexion Pharmaceuticals, Inc.

Founded in 1992, Alexion Pharmaceuticals is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. The Company's three highly innovative therapies treat patients with four severe and ultra-rare diseases. Alexion Pharma is headquartered in New Haven, Connecticut.

Stock Performance Snapshot

December 27, 2017 - At Wednesday's closing bell, Alexion Pharma's stock marginally climbed 0.49%, ending the trading session at $119.80.

Volume traded for the day: 1.30 million shares.

Stock performance in the last month - up 11.18%

After yesterday's close, Alexion Pharma's market cap was at $26.64 billion.

Price to Earnings (P/E) ratio was at 53.55.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors